Regeneron Pharmaceuticals Inc.

(NASDAQ:REGN) Trade

By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products including: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.

Contact Information

Website: www.regeneron.com
Email: manisha.narasimhan@regeneron.com
Main Phone: +1 914 847-7000
Address: 777 Old Saw Mill River Road
State: NY
City / Town: Tarrytown
Country: US
Postal Code: 10591-6707

Issuer Information

Exchange: NGS
CEO: Leonard S. Schleifer
Employees: 9123
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

View More
(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A